IP Library Granted Patent US 11,427,535
Granted Patent B2
US 11,427,535 · App. 17/172,640 · Granted Aug 30, 2022

Polyanionic delivery of nucleic acids

Inventors: Michael Heartlein (Lexington, MA); Frank DeRosa (Lexington, MA); Shrirang Karve (Lexington, MA)
Assignee: Translate Bio, Inc.
C07C305/06A61K9/1272A61K31/7105A61K47/543A61K47/58C07C317/18
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,427,535
App. No.
17/172,640
Granted
Aug 30, 2022
Kind
B2
Abstract

Disclosed are dendritic anionic lipids which are compounds of Formula (I): wherein R and R 1 are non-polar groups, L is a linking moiety, and Dm is a dendritic moiety of m generations, each as defined herein. These dendritic anionic lipids are useful for delivery and expression of m RNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.

Claims (14)

1. A compound selected from the group consisting of:

2. The compound of claim 1 , wherein said compound has the following structure:

3. The compound of claim 1 , wherein said compound has the following structure:

4. The compound of claim 1 , wherein said compound has the following structure:

5. A composition comprising an mRNA encoding a protein, encapsulated within a liposome, wherein the liposome comprises one or more cationic lipids, one or more non-cationic lipids, one or more cholesterol-based lipids and one or more PEG-modified lipids, wherein at least one non-cationic lipid is the compound of claim 1 .

6. The composition of claim 5 , comprising an mRNA encoding for cystic fibrosis transmembrane conductance regulator (CFTR) protein.

7. The composition of claim 5 , comprising an mRNA encoding for ornithine transcarbamylase (OTC) protein.

8. A composition comprising a nucleic acid encapsulated within a liposome, wherein the liposome comprises the compound of claim 1 .

9. The composition of claim 8 , further comprising one more lipids selected from the group consisting of one or more cationic lipids, one or more non-cationic lipids, and one or more PEG-modified lipids.

10. The composition of claim 8 , wherein the nucleic acid is an mRNA encoding a peptide or polypeptide.

11. The composition of claim 10 , wherein the mRNA encodes a peptide or polypeptide for use in the delivery to or treatment of the lung of a subject or a lung cell.

12. The composition of claim 11 , wherein the mRNA encodes cystic fibrosis transmembrane conductance regulator (CFTR) protein.

13. The composition of claim 10 , wherein the mRNA encodes a peptide or polypeptide for use in the delivery to or treatment of the liver of a subject or a liver cell.

14. The composition of claim 13 , wherein the mRNA encodes ornithine transcarbamylase (OTC) protein.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2021
From: HEARTLEIN, MICHAEL; DEROSA, FRANK; KARVE, SHRIRANG
To: TRANSLATE BIO MA, INC.
Reel/Frame 057414/0102 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2021
From: TRANSLATE BIO MA, INC.
To: TRANSLATE BIO, INC.
Reel/Frame 057414/0113 →
Continuity (3)
Continuation 16491475
Provisional Application 62468244 · Mar 7, 2017
Related Publication 20210261502A1 · Aug 26, 2021